NEBIVOLOL IN COMBINATION WITH TEMPOL IMPROVES METABOLIC AND HEMODINAMIC PARAMETERS IN A MODEL OF METABOLIC SYNDROME

SANTANDER Y.; BOQUETE C.; ALLO M.; PAROLA L.; DEL MAURO J.S.; CARRANZA A.; POLIZIO A.; GORZALCZANY S.B.; CHIAPPETTA D.A.; DONATO M.; HOCHT C.; TAIRA C.

Encuentro; REUNIÓN CONJUNTA DE SOCIEDADES DE BIOCIENCIAS; 2017

The metabolic syndrome (MS) is a constellation of metabolic abnormalities such as glucose intolerance, hipertrigliceridemia, hypertension and inflammation that predispose to type 2 diabetes and cardiovascular diseases. The therapeutic arsenal of hypertension is composed by several pharmacology groups. Beta blockers have a lower benefit in the treatment of essential hypertension compared with other drugs. However in the last years, have been arouse the third generation beta blockers, like nebivolol, which enhances of NO dependent vasodilatation. Tempol is an antioxidant that mimics the action of the superoxide dismutase enzyme, that catalyses the conversion of O2˙- into H2O2, and the consequent reduction of blood pressure. The aim of this work was to evaluate the effects of nebivolol, alone or combined with tempol, on systolic blood pressure (SBP), the echocardiography and metabolic parameters in a model of metabolic syndrome. Male Sprague Dawley rats (250-300g) with or without fructose (F) (10% w/v) in tap water during 12 weeks, were distributed in 4 groups (n=6): control, Nebivolol (15 mg/kg/day/ i.g.), Tempol (60 mg/Kg/day/i.g) and nebivolol + tempol. All groups were evaluated for indirect SBP by tail-cuff method, echocardiography Doppler and oral glucose Tolerance test (OGTT). In comparison with normotensive rats, F overloaded rats showed an increase of indirect SBP (mmHg, C: 120±2 vs F: 138±4, p